Education
About Us
Working with TipRanks
Follow Us
Replimune Group (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
$7.04
$0.17(1.56%)
At close: 4:00 PM EST
$7.04
$0.17(1.56%)
Day’s Range― - ―
52-Week Range$2.68 - $14.80
Previous CloseN/A
Volume95.41K
Average Volume (3M)1.29M
Market Cap
$552.24M
Enterprise Value$526.27M
Total Cash (Recent Filing)$323.64M
Total Debt (Recent Filing)$76.32M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding78,443,340
10 Day Avg. Volume1,409,999
30 Day Avg. Volume1,289,733
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.89
Price to Sales (P/S)0.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-620.60
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$11.43Price Target Upside62.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.21
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyConsistent objective responses in the IGNYTE trial combined with a relatively benign safety profile strengthen the argument that RP1 plus PD‑1 therapy could become an effective option for refractory melanoma.
Financial Position And Analyst SupportA strong cash position that extends the company through upcoming catalysts, together with analyst upgrades and higher price targets, signals increased market confidence in the program's commercial prospects.
Regulatory ProgressFDA acceptance of the BLA resubmission for RP1 with nivolumab advances the application toward a regulatory decision and reduces near-term regulatory ambiguity.
Bears Say
Data Robustness ConcernsSkepticism persists that single-arm IGNYTE data may be insufficient for accelerated approval, which could lead regulators to demand more rigorous, randomized evidence.
Regulatory Setbacks And Trial RequirementsThe prior Complete Response Letter citing patient heterogeneity and study design gaps raises the risk that regulators could require additional or rerun studies, increasing development costs and timelines.
Regulatory Volatility Impact On ValuationOngoing back-and-forth with the agency creates regulatory volatility that could depress the stock if further setbacks occur or if approval timing remains uncertain.
Replimune Group News
REPL FAQ
What was Replimune Group’s price range in the past 12 months?
Replimune Group lowest stock price was $2.68 and its highest was $14.79 in the past 12 months.
What is Replimune Group’s market cap?
Replimune Group’s market cap is $552.24M.
When is Replimune Group’s upcoming earnings report date?
Replimune Group’s upcoming earnings report date is May 14, 2026 which is in 114 days.
How were Replimune Group’s earnings last quarter?
Replimune Group released its earnings results on Nov 06, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.74 by -$0.16.
Is Replimune Group overvalued?
According to Wall Street analysts Replimune Group’s price is currently Undervalued.
Does Replimune Group pay dividends?
Replimune Group does not currently pay dividends.
What is Replimune Group’s EPS estimate?
Replimune Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Replimune Group have?
Replimune Group has 78,443,340 shares outstanding.
What happened to Replimune Group’s price movement after its last earnings report?
Replimune Group reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.74. Following the earnings report the stock price went down -0.932%.
Which hedge fund is a major shareholder of Replimune Group?
Currently, no hedge funds are holding shares in REPL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.43 (62.36% Upside)
$11.43 (62.36% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.04%
12-Months-Change
Fundamentals
Return on Equity
-96.24%
Trailing 12-Months
Asset Growth
-21.83%
Trailing 12-Months
Company Description
Replimune Group
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Stock 12 Month Forecast
Average Price Target
$11.43
▲(62.36% Upside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---